Hibiscus Study: An oral investigational medication for SCD
What is this?
The Sickle Cell 101 research team in collaboration with study investigator have reviewed this information to ensure it is patient-friendly and accurate.
About the Study
The Hibiscus Study is enrolling adults and adolescents 12 to 65 years old with a clinical diagnosis of SCD. The primary purpose of the study is to evaluate the safety and effectiveness of an oral investigational medication for SCD.
The investigational medication is being tested to see how well it works compared to placebo (inactive substance) to improve anemia and reduce the number of pain crises per year. The investigational medication or placebo are given as two tablets taken one time per day. The study length is 52 weeks, followed by an optional additional 52 week extension study, where all participants will receive investigational medication. A separate consent form will need to be signed to take part in the extension study. Study-specific investigational medication, medical exams and laboratory tests are available to you at no cost. Reimbursement for time and travel, as well as transportation to and from your study visits, may also be available to you.